Results 221 to 230 of about 32,948 (259)
Some of the next articles are maybe not open access.
Disease-a-Month, 1992
Polycythemia vera (PV) is one of the myeloproliferative diseases, and, as such, is an example of clonal hematopoiesis. The progeny of a single, abnormal, hematopoietic stem cell gain a growth advantage over their normal counterparts resulting in overproduction of red cells generally accompanied by overproduction of granulocytes and platelets as well ...
DEWOLF, JTM, VELLENGA, E, HALIE, MR
openaire +4 more sources
Polycythemia vera (PV) is one of the myeloproliferative diseases, and, as such, is an example of clonal hematopoiesis. The progeny of a single, abnormal, hematopoietic stem cell gain a growth advantage over their normal counterparts resulting in overproduction of red cells generally accompanied by overproduction of granulocytes and platelets as well ...
DEWOLF, JTM, VELLENGA, E, HALIE, MR
openaire +4 more sources
Journal of the American Academy of Nurse Practitioners, 1999
Although no cure exists for PV, treatment can prolong lives and enhance the quality-of-life for patients affected by this condition (Talarico, 1998). The insidious onset may make diagnosis difficult, but PV should be suspected when any patient presents with an elevated hematocrit.
Kerri Lantz Petersen, Lorna Schumann
openaire +2 more sources
Although no cure exists for PV, treatment can prolong lives and enhance the quality-of-life for patients affected by this condition (Talarico, 1998). The insidious onset may make diagnosis difficult, but PV should be suspected when any patient presents with an elevated hematocrit.
Kerri Lantz Petersen, Lorna Schumann
openaire +2 more sources
Current Treatment Options in Oncology, 2018
Polycythemia vera (PV) is the most common myeloproliferative neoplasm (MPN), the ultimate phenotype of the JAK2 V1617F mutation, the MPN with the highest incidence of thromboembolic complications, which usually occur early in the course of the disease, and the only MPN in which erythrocytosis occurs. The classical presentation of PV is characterized by
openaire +2 more sources
Polycythemia vera (PV) is the most common myeloproliferative neoplasm (MPN), the ultimate phenotype of the JAK2 V1617F mutation, the MPN with the highest incidence of thromboembolic complications, which usually occur early in the course of the disease, and the only MPN in which erythrocytosis occurs. The classical presentation of PV is characterized by
openaire +2 more sources
Seminars in Oncology Nursing, 1996
To review the proliferative nature of polycythemia vera (PV), clinical features, laboratory findings, treatment options and controversies, and nursing management.Textbook chapters and review articles that pertain to polycythemia vera.Polycythemia vera is a chronic myeloproliferative disorder that can evolve into acute leukemia.
openaire +2 more sources
To review the proliferative nature of polycythemia vera (PV), clinical features, laboratory findings, treatment options and controversies, and nursing management.Textbook chapters and review articles that pertain to polycythemia vera.Polycythemia vera is a chronic myeloproliferative disorder that can evolve into acute leukemia.
openaire +2 more sources
Polycythemia vera and other primary polycythemias
Current Opinion in Hematology, 2005Diagnosis and therapy of polycythemia vera are controversial since the molecular basis of polycythemia vera remains unknown. Distinguishing between polycythemia vera and other polycythemic disorders can be very challenging. The purpose of this review is to discuss the recent progress in this area and critically review the published data in context of ...
openaire +2 more sources
Southern Medical Journal, 1928
Since 1918, when Eppinger and Kloss first used phenylhydrazine hydrochloride clinically in the treatment of polycythemia vera, several reports of cases so treated have been presented in the literature with varying conclusions drawn therefrom. I have not found any report, however, covering as long a period of continuous treatment as in the case which ...
openaire +2 more sources
Since 1918, when Eppinger and Kloss first used phenylhydrazine hydrochloride clinically in the treatment of polycythemia vera, several reports of cases so treated have been presented in the literature with varying conclusions drawn therefrom. I have not found any report, however, covering as long a period of continuous treatment as in the case which ...
openaire +2 more sources
Journal of the American Medical Association, 1932
In April, 1928, I 1 reported a case of polycythemia vera which had been under observation and treatment with phenylhydrazine hydrochloride for three and one-half years and drew the following tentative conclusions from my experience with this case: The erythrocyte count may be kept near normal limits by the periodic administration of 2.1 Gm.
openaire +1 more source
In April, 1928, I 1 reported a case of polycythemia vera which had been under observation and treatment with phenylhydrazine hydrochloride for three and one-half years and drew the following tentative conclusions from my experience with this case: The erythrocyte count may be kept near normal limits by the periodic administration of 2.1 Gm.
openaire +1 more source
American family physician, 2004
Polycythemia vera is a chronic myeloproliferative disorder characterized by increased red blood cell mass. The resultant hyperviscosity of the blood predisposes such patients to thrombosis. Polycythemia vera should be suspected in patients with elevated hemoglobin or hematocrit levels, splenomegaly, or portal venous thrombosis.
Brian J, Stuart, Anthony J, Viera
openaire +1 more source
Polycythemia vera is a chronic myeloproliferative disorder characterized by increased red blood cell mass. The resultant hyperviscosity of the blood predisposes such patients to thrombosis. Polycythemia vera should be suspected in patients with elevated hemoglobin or hematocrit levels, splenomegaly, or portal venous thrombosis.
Brian J, Stuart, Anthony J, Viera
openaire +1 more source